|ELISA (ELISA)||Assay Dependent|
|Immunocytochemistry (ICC)||Assay Dependent|
|Immunofluorescence (IF)||Assay Dependent|
|Immunohistochemistry (IHC)||Assay Dependent|
|Immunoprecipitation (IP)||0.1-0.5 µg/ml|
|Western Blot (WB)||0.5 µg/ml|
|Immunohistochemistry (Paraffin) (IHC (P))||See 1 publications below|
|Immunohistochemistry (IHC)||See 6 publications below|
|Western Blot (WB)||See 3 publications below|
|Immunofluorescence (IF)||See 2 publications below|
|Species reactivity||Human, Mouse, Rat|
|Published species||Human, Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide derived from the region surrounding the phosphorylated Tyr1086 residue of the human, mouse, rat, and pig epidermal growth factor receptor (EGFr) protein.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.4|
|Contains||0.1% sodium azide|
EGFR (Epidermal growth factor receptor, HER1, ErbB1) is encoded by the EGFR gene located on chromosome 7 in humans. EGFR belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain. Phosphorylation of EGFR at certain residues is also mediated by Src-non-receptor kinase. EGFR activation signals multiple downstream signaling cascades such as the Ras - ERK, PI3-K - Akt, Jak - STAT and PKC pathways that help in growth and proliferation of cells. Phosphorylation of EGFR at Y1086 specifically allows binding of the adaptor protein GRB2, leading to activation of the MAPK pathway. Upon receptor activation and signaling, EGFR is endocytosed and targeted for degradation or recycling. Mutations in the EGFR gene are associated with lung cancer and multiple alternatively spliced transcript variants encode different protein isoforms of EGFR have been found. Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. Moreover, EGFR overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; avian erythroblastic leukemia viral (v-erbB) oncogene homolog; cell growth inhibiting protein 40; cell proliferation-inducing protein 61; EC 126.96.36.199; EGFR-related peptide; Epidermal growth factor receptor; Epidermal growth factor receptor formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1); Epidermal growth factor receptor precursor; epidermal growth factor receptor, formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1); erb-b2 receptor tyrosine kinase 1; ERBB1; kinase EGFR; Proto-oncogene c-ErbB-1; Receptor protein-tyrosine kinase ErbB-1; Receptor tyrosine-protein kinase erbB-1; waved 2
Gene Aliases: 9030024J15Rik; AI552599; EGFR; ERBB; ErbB-1; ERBB1; Errb1; Errp; HER1; mENA; NISBD2; PIG61; wa-2; wa2; Wa5
If an Invitrogen™ antibody doesn’t perform as described on our website or datasheet, we’ll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.